Amanita Muscaria Fruiting Body Ambergris Barium Ca
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Amanita Muscaria Fruiting Body Ambergris Barium Ca
- Multi-Ingredient Mixture (Amanita Muscaria / Colchicum / Convallaria et al.): Insufficient Data for Repurposing Evaluation
Multi-Ingredient Mixture (Amanita Muscaria / Colchicum / Convallaria et al.): Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This candidate is a heterogeneous mixture of 12 ingredients spanning toxic fungi, heavy metal salts, cardiac glycoside plants, and botanical extracts, with no confirmed single INN or DrugBank identifier. The TxGNN pipeline returned no predicted indications for this combination, and there is currently no regulatory approval in the US market. Due to the absence of a unified pharmacological profile and the presence of multiple known toxic components, this candidate cannot proceed to standard repurposing evaluation at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only; in this case no prediction returned) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was generated for this candidate. The pipeline was unable to map this multi-ingredient string to a single DrugBank node, which is a prerequisite for the knowledge-graph and deep-learning scoring steps.
The 12 listed components span radically different pharmacological classes and safety profiles:
- Amanita muscaria fruiting body — psychoactive/toxic mushroom containing ibotenic acid and muscimol
- Barium carbonate — inorganic heavy metal salt with known systemic toxicity
- Colchicum autumnale bulb — source of colchicine, a narrow therapeutic-index alkaloid
- Convallaria majalis — contains cardiac glycosides (convallatoxin); classified as highly toxic
- Semecarpus anacardium juice — contains urushiol-like compounds with strong irritant and cytotoxic properties
Given this composition, even if a prediction were generated, the mixture does not map to a single mechanism of action that could justify repurposing evaluation under standard criteria. Each component would need independent safety and pharmacokinetic characterization before any combined assessment is possible.
Clinical Trial Evidence
Currently no related clinical trials registered for this multi-ingredient combination.
Literature Evidence
Currently no related literature available for this specific combination as a unified therapeutic entity.
Safety Considerations
No formal safety data is available in this Evidence Pack. However, based on the known toxicological profiles of the individual ingredients, the following concerns are flagged for awareness:
- Amanita muscaria: Contains neurotoxic/psychoactive alkaloids (muscimol, ibotenic acid); ingestion causes cholinergic and anticholinergic toxidrome
- Barium carbonate: Water-soluble barium salts are acutely toxic; causes hypokalemia, cardiac arrhythmia, and paralysis
- Colchicum autumnale: Colchicine has a narrow therapeutic index; overdose causes multi-organ failure
- Convallaria majalis: Cardiac glycoside toxicity — bradycardia, heart block, ventricular arrhythmia
- Semecarpus anacardium: Severe contact and systemic irritant; potential nephrotoxic and hepatotoxic effects
These components collectively present high aggregate toxicity risk. Formal toxicological profiling of the complete mixture is required before any further evaluation.
Conclusion and Next Steps
Decision: Hold
Rationale: The candidate cannot be evaluated under the standard TxGNN drug repurposing framework because (1) it cannot be resolved to a single DrugBank entity, (2) the TxGNN pipeline produced no indication predictions, and (3) multiple individual ingredients carry significant known toxicity that precludes standard benefit-risk assessment without further preclinical characterization.
To proceed, the following is needed:
- Clarify whether this combination represents a registered homeopathic product or an experimental formulation — this determines which regulatory pathway applies
- Identify the active therapeutic ingredient(s) intended to drive efficacy, and evaluate those individually through TxGNN
- Conduct individual ingredient toxicological profiling for the five high-risk components listed above (Amanita, Barium carbonate, Colchicum, Convallaria, Semecarpus)
- Obtain or create a DrugBank mapping for any single component designated as the primary active ingredient before re-submitting to the TxGNN pipeline
- If a homeopathic formulation, confirm that ingredient concentrations fall within regulatory homeopathic dilution standards that mitigate acute toxicity concerns
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.